Unresectable HER2-low breast carcinoma

Clinical trials for Unresectable HER2-low breast carcinoma explained in plain language.

Never miss a new study

Get alerted when new Unresectable HER2-low breast carcinoma trials appear

Sign up with your email to follow new studies for Unresectable HER2-low breast carcinoma, keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Trials to join now! 1

Experimental drug combo targets Hard-to-Treat HER2 cancers

Disease control Recruiting now

This early-phase trial tests the safety and best dose of a new drug combination—pidnarulex plus trastuzumab deruxtecan—in people with advanced breast cancer and other solid tumors that have the HER2 protein. The study enrolls 36 adults whose cancer has spread or cannot be surgica…

Matched conditions: UNRESECTABLE HER2-LOW BREAST CARCINOMA

Phase 1 • Sponsor: National Cancer Institute (NCI) • Aim: Disease control

Last updated Jul 15, 2026 00:00 UTC

Unresectable HER2-low breast carcinoma

Get alerted when new Unresectable HER2-low breast carcinoma trials appear

Experimental drug combo targets Hard-to-Treat HER2 cancers